Weight Management in Diabetes

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee

Sean Wharton MD, FRCPC, PharmD Arya M. Sharma MD, PhD, FRCPC David C.W. Lau MD, PhD, FRCPC

  • Key Messages
  • Recommendations
  • Figures
  • Full Text
  • References

Key Messages

  • An estimated 80% to 90% of persons with type 2 diabetes are overweight or obese. Higher body mass index in people with diabetes is associated with increased overall mortality.
  • A modest weight loss of 5% to 10% of initial body weight can substantially improve glycemic control and cardiovascular disease risk factors.
  • Comprehensive health behaviour intervention should be implemented in overweight and obese people with diabetes or those at risk for diabetes to prevent weight gain and to achieve and maintain a reduced body weight. Many classes of antihyperglycemic medications are associated with weight gain, while some are weight neutral or associated with weight loss. The drug effects on body weight should be considered in glycemic management.
  • Bariatric surgery may be considered for appropriate patients when other interventions fail to achieve and maintain a healthy body weight.


Obesity is widely considered a chronic health problem that is often progressive and difficult to treat. An estimated 80% to 90% of persons with type 2 diabetes are also overweight or obese (1). Obesity is also becoming more prevalent in people with type 1 diabetes; a study has indicated a 7-fold increase in obesity in 20 years (2). Furthermore, intensive insulin therapy and some glucose-lowering medications are associated with weight gain (3,4). Weight loss has been shown to improve glycemic control by increasing insulin sensitivity and glucose uptake and diminishing hepatic glucose output (5). The risk of death from all causes, cardiovascular disease (CVD) and some forms of cancer increases with excessive body fat (6). This relationship between increasing body fat accumulation and adverse health outcomes exists throughout the range of overweight and obese men and women in all age groups, including those ≥75 years of age (7). Analysis of 57 prospective studies in ∼900,000 adults by the Prospective Studies Collaboration indicated that each 5 kg/m2 higher body mass index (BMI) above 25 kg/m2 was associated with about 30% higher overall mortality (8).

Assessment of Overweight and Obesity

The initial assessment of people with diabetes should include the following measurements: height, weight, calculation of BMI (kg/m2) (Table 1) (9) and waist circumference (WC) to assess the degree of abdominal obesity (Table 2) (9). Metabolic comorbidities, such as hypertension, dyslipidemia and CVD risk factors, should also be assessed since they are highly correlated with increasing BMI (10,11). Excessive abdominal adiposity is a strong independent predictor of metabolic comorbidities (12,13). Cutoff values for WC vary among expert guidelines. Table 2 (14,15) lists National Cholesterol and Education Program Adult Treatment Panel III (NCEP-ATP III) WC values. The International Diabetes Federation has proposed population specific WC cutoff values (Table 3) (16). These guidelines have not been fully validated against the development of clinical events, and considerable population-based research is needed in this area.

Table 1
Canadian guidelines for body weight classification in adults using BMI (8)
 Body mass index (BMI) values are age and gender independent and may not be correct for all ethnic populations.
Classification BMI category (kg/m2) Risk of developing health problems
Underweight <18.5 Increased
Normal weight 18.5–24.9 Least
Overweight 25.0–29.9 Increased
Obese ≥30.0  
    Class I 30.0–34.9 High
    Class II 35.0–39.9 Very High
    Class III ≥40.0 Extremely High

Assessment of overweight and obese patients should include determining reasons for the previous or current positive energy balance that led them to become overweight or obese, or to continually gain weight. An etiological approach assessing causes of lower metabolic rates, such as medications and hormonal imbalances, should be considered (17). People with diabetes often take medications that are associated with weight gain; these include antihyperglycemic, antihypertensive, pain relief and antidepressant agents (18). Psychological aspects of eating behaviours, such as emotional eating, binge eating and depression, also should be assessed (19). Physical parameters that impede activity, such as osteoarthritis or dyspnea, should be assessed (20). Comorbid conditions, such as osteoarthritis and obstructive sleep apnea, can also impact the ability to lose weight (21). These conditions should be assessed and treated.

Table 2
NCEP-ATP III WC and risk of developing health problems (8)
 Waist circumference (WC) cutoffs may be lower in some populations (e.g. older individuals, Asian population [See Table 3]), especially in the presence of the metabolic syndrome (e.g. hypertriglyceridemia).
WC cutoff points∗,† Risk of developing health problems
Men ≥102 cm (40 inches) Increased
Women ≥88 cm (35 inches) Increased
Table 3
Ethnic-specific values for WC from International Diabetes Federation(13)
National Cholesterol and Education Program Adult Treatment Panel III (NCEP-ATP III) guidelines (11,12) and Health Canada (6) define central obesity as waist circumference (WC) values ≥102 cm (40 inches) in men and ≥88 cm (35 inches).
Country or ethnic group Central obesity as defined by WC
  Men Women
Europid ≥94 cm ≥80 cm
South Asian, Chinese, Japanese ≥90 cm ≥80 cm
South and Central American Use South Asian cutoff points until more specific data are available.
Sub-Saharan African Use Europid cutoff points until more specific data are available.
Eastern Mediterranean and Middle Eastern (Arab) Use Europid cutoff points until more specific data are available.
Table 4
Checklist for weight management programs (46)
  1. The program assesses and treats comorbid conditions.
  2. The program provides individualized nutritional, exercise and behavioral programs and counselling.
  3. Nutritional advice is provided by qualified experts (e.g. registered dietitians) and diets are not less than 900 kcal/day.
  4. Exercise is encouraged but physical activity is promoted at a gradual pace.
  5. >Reasonable weight loss goals are set at 1 to 2 lb/week.
  6. Cost is not prohibitive, and there are no financial contracts.
  7. There is no requirement to buy products, supplements, vitamins or injections.
  8. The program does not make unsubstantiated claims.
  9. The program has an established maintenance program.

Treatment of Overweight and Obesity

The goals of therapy for overweight and obese people with diabetes are to achieve optimal glycemic and metabolic control initially through health behaviour intervention. Attaining and maintaining a healthy body weight and preventing weight regain are the short- and long-term goals. In general, obese people with diabetes have greater difficulty with weight loss compared to similarly obese people without diabetes (22). Many antihyperglycemic medications are associated with weight gain, and attempts should be made to minimize these medications without compromising glycemic control or to switch to alternative agents not associated with weight gain (18). For many patients, prevention of weight gain can be considered a realistic and sustainable outcome. A modest weight loss of 5% to 10% of initial body weight can substantially improve insulin sensitivity, glycemic control, high blood pressure (BP) and dyslipidemia (23–27). The optimal rate of weight loss is 1 to 2 kg/month but is generally self-limiting due to physiological counterregulation (17,28). A negative energy balance of 500 kcal/day is typically required to achieve a weight loss of 0.45 kg/week (29). As individuals lose weight, adjustment in antihyperglycemic medications may be required to avoid hypoglycemia.

Table 5
Medication approved for the treatment of obesity in type 2 diabetes (36)
Class Generic (trade) name Recommended regimen Action Adverse effects
Gastrointestinal lipase inhibitor Orlistat (Xenical) 120 mg tid (during or up to 1 hour after each meal)
  • Nonsystemic pancreatic lipase inhibitor reduces dietary fat digestion and absorption by about 30%
  • Abdominal bloating, pain and cramping
  • Steatorrhea
  • Fecal incontinence

The National Institutes of Health (NIH)-sponsored multicenter Look AHEAD (Action for Health in Diabetes) trial, whose design is based largely on the United States (US) Diabetes Prevention Program, investigated the effects of lifestyle intervention on changes in weight, fitness, and CVD risk factors and events in people with type 2 diabetes (30). The 1- and 4-year interim data reported beneficial effects of modest weight loss of 5% to 10% in improving glycemic control, lowering of CV risk markers, BP and lipid levels (30,31). Greater improvement in risk factors occurred with greater weight losses. There was some expected weight regain at 4 years, yet there continued to be beneficial metabolic effects.

Table 6
Glucose-lowering medications and their effects on weight (17)
Weight gain Weight effect (lb)
Insulin (fast acting, NPH) (2) +8.8 – +11.0
Thiazolidinediones (TZDs) (57) +5.2 – +10.6
Sulphonylureas (2,57) +3.5 – +5.7
Meglitinides (58) +1.54 – +3.97
Weight neutral or decrease weight Weight effect
Insulin (basal analogues, detemir, glargine) (59,60) −0.22 – +0.88
Metformin (61) −8.4 – +0.88
Alpha-glucosidase inhibitors (62,63) +0.0 – +0.44
Dipeptidyl peptidase-4 (DPP-4) inhibitors (64,65) +0.0 – +0.46
Glucagon-like peptide-1 (GLP-1) receptor agonists (66,67)     −6.6 – −3.5

Healthy Behaviour Interventions

The overall goal of health behaviour intervention in people with diabetes who are overweight or obese is to improve health status and quality of life (32,33).

Health behaviour interventions that combine dietary modification, increased and regular physical activity and behaviour therapy are the most effective (34–37). Structured interdisciplinary programs have demonstrated better short- and long-term results (36).

All weight-loss diets must be well balanced and nutritionally adequate to ensure optimal health. In general, a carbohydrate intake of at least 100 g/day is required to spare protein breakdown and muscle wasting and to avoid large shifts in fluid balance and ketosis. High-fibre foods are associated with greater satiety. Adequate protein intake is required to maintain lean body mass and other essential physiological processes. Reduced intake of saturated fat and energy-dense foods should be emphasized. Very-low-calorie diets with <900 kcal/day are not recommended, except under medical supervision.

As understanding and adhering to healthy and nutritionally balanced meal plans can be challenging, people with diabetes should be counselled by qualified professionals on appropriate serving sizes, caloric and carbohydrate intake and how to select nutrient-rich meals (38,39).

Two large-scale reviews of >100 individual studies evaluating behaviour modification techniques support their effectiveness in promoting weight loss (40,41).

Members of the healthcare team should consider using a structured approach to providing advice and feedback on physical activity, healthy eating habits and weight loss (42–45). Programs and clinics dedicated to weight management may be beneficial, particularly those that adhere to the checklist in Table 4 (46).

Figure 1
Biliopancreatic Diversion with Duodenal Switch.

The stomach and small intestine are surgically reduced so that nutrients are absorbed only in a 50-cm “common limb.” (From Shukla A, Rubino F. Secretion and function of gastrointestinal hormones after bariatric surgery: their role in type 2 diabetes. Can J Diabetes 2011;35:115-122.)

Figure 2
Roux-en-Y Gastric Bypass.

A surgical stapler is used to create a small gastric pouch. Ingested food bypasses ∼95% of the stomach, the entire duodenum and a portion of the jejunum. (From Shukla A, Rubino F. Secretion and function of gastrointestinal hormones after bariatric surgery: their role in type 2 diabetes. Can J Diabetes 2011;35:115-122.)

Figure 3
Gastric Sleeve.

A longitudinal (sleeve) resection of the stomach reduces the functional capacity of the stomac and eliminates the ghrelin-rich gastric fundus. (From Shukla A, Rubino F. Secretion and function of gastrointestinal hormones after bariatric surgery: their role in type 2 diabetes. Can J Diabetes 2011;35:115-122.)

Figure 4
Adjustable Gastric Band.

The upper part of the stomach is encircled with a constrictive saline-filled tube. The amount of restriction can be adjusted by injecting or withdrawing saline solution. (From Shukla A, Rubino F. Secretion and function of gastrointestinal hormones after bariatric surgery: their role in type 2 diabetes. Can J Diabetes 2011;35:115-122.)


Orlistat is currently the only approved medication in Canada for long-term management of obesity (Table 5) (47). When used to treat overweight and obese people with diabetes, orlistat has been demonstrated to improve glycemic control and to reduce the doses of antihyperglycemic agents that can promote weight gain (47).

However, pharmacotherapy options are limited in weight management, and many approved agents have been discontinued by the developers or rejected by government drug approval boards due to unacceptable side effects (18). Pharmacotherapy can be considered for people with BMI ≥30.0 kg/m2 with no obesity-related comorbidities or risk factors, or for those with BMI ≥27.0 kg/m2 with obesity-related comorbidities or risk factors (29). Antiobesity drug therapy may be considered as an adjunct to nutrition therapy, physical activity and behaviour modification to achieve a target weight loss of 5% to 10% of initial body weight and for weight maintenance (32,48). There are several new antiobesity agents that may be available within the near future and that may have a beneficial impact on diabetes management.

Orlistat leads to greater weight loss when coupled with healthy behaviour interventions (47). Orlistat has been shown to be effective at improving glycemic and metabolic control in obese people with type 2 diabetes (47,49,50). In obese people with impaired glucose tolerance, orlistat also improves glucose tolerance and reduces the progression to type 2 diabetes (51). Clinical trials with antiobesity agents have confirmed a smaller degree of weight loss in people with diabetes compared with obese people who do not have diabetes (22,38). Orlistat should be avoided in patients with inflammatory or other chronic bowel disease.

Some antihyperglycemic medications are associated with weight gain (insulin, insulin secretagogues, thiazolidinediones), and the magnitude of weight gain can vary from 4 to 9 kg or more, depending on the choice of drugs (Table 6 ) (18). Insulin is associated with the most weight gain, whereas metformin, glucosidase inhibitors and the incretin class of antihyperglycemic agents typically are weight neutral or associated with a weight loss of about 3 kg (18).

Other available anti-obesity drugs, such as diethylpropion and phentermine, are sympathomimetic noradrenergic appetite suppressants that are approved only for short-term use of a few weeks. They are not recommended because of modest efficacy and frequent adverse side effects.

Bariatric Surgery

Bariatric surgery has emerged as an innovative alternative option in the management of type 2 diabetes. These procedures can result in sustained body weight loss and significant improvement in obesity-related comorbidities (52). Surgery is usually reserved for people with class III obesity (BMI ≥40.0 kg/m2) or class II obesity (BMI = 35.0 to 39.9 kg/m2) in the presence of comorbidities (52) and the inability to achieve weight loss maintenance following an adequate trial of health behaviour intervention. Individuals who are candidates for surgical procedures should be selected after evaluation by an interdisciplinary team with medical, surgical, psychiatric and nutritional expertise. Long-term, if not lifelong, medical surveillance after surgical therapy is necessary for most people. Bariatric surgery procedures can be classified as restrictive, malabsorptive or combined restrictive and malabsorptive. Biliopancreatic diversion with duodenal switch procedure (Figure 1), roux-en-Y gastric bypass (Figure 2), gastric sleeve (Figure 3) and laparoscopic adjustable gastric banding (Figure 4 ) have all demonstrated significant improvements and even remission in type 2 diabetes (53–55).


  1. An interdisciplinary weight management program (including a nutritionally balanced, calorie-restricted diet; regular physical activity; education; and counselling) for overweight and obese people with, or at risk for, diabetes should be implemented to prevent weight gain and to achieve and maintain a lower, healthy body weight [Grade A, Level 1A (30,56) ].
  2. In overweight or obese adults with type 2 diabetes, the effect of antihyperglycemic agents on body weight should be taken into account [Grade D, Consensus].
  3. Adults with type 2 diabetes and class II or III obesity (BMI ≥35.0 kg/m2) may be considered for bariatric surgery when lifestyle interventions are inadequate in achieving healthy weight goals [Grade B, Level 2 (53–55) ].

Other Relevant Guidelines

Physical Activity and Diabetes, p. S40

Nutrition Therapy, p. S45


  1. 1 R.R. Wing Weight loss in the management of type 2 diabetes H.C. Gerstein B. Haynes Evidence-Based Diabetes Care 2000 B.C. Decker, Inc Ontario, Canada 252 276
  2. 2 B. Conway R.G. Miller T. Costacou Temporal patterns in overweight and obesity in type 1 diabetes Diabet Med 27 2010 398 404
  3. 3 UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
  4. 4 N. Ruderman D. Chisholm X. Pi-Sunyer The metabolically obese, normal-weight individual revisited Diabetes 47 1998 699 713
  5. 5 T.P. Markovic A.B. Jenkins L.V. Campbell The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM Diabetes Care 21 1998 687 694
  6. 6 E.E. Calle C. Rodriguez K. Walker-Thurmond Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638
  7. 7 J. Stevens J. Cai E.R. Pamuk The effect of age on the association between body-mass index and mortality N Engl J Med 338 1998 1 7
  8. 8 Prospective Studies Collaboration Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies Lancet 373 2009 1083 1096
  9. 9 Health Canada Canadian Guidelines for Body Weight Classification in Adults Publication H49–179/2003E 2003 Health Canada Ottawa, ON
  10. 10 S.W. Rabkin Y. Chen L. Leiter Risk factor correlates of body mass index. Canadian Heart Health Surveys Research Group CMAJ 157 suppl 1 1997 S26 S31
  11. 11 World Health Organization Obesity: preventing and managing the global epidemic. Report of a WHO consultation World Health Organ Tech Rep Ser 894 2000 1 253 i-xii
  12. 12 B.A. Reeder A. Senthilselvan J.P. Després The association of cardiovascular disease risk factors with abdominal obesity in Canada. Canadian Heart Health Surveys Research Group CMAJ 157 suppl 1 1997 S39 S45
  13. 13 J.P. Després I. Lemieux D. Prud’homme Treatment of obesity: need to focus on high risk abdominally obese patients BMJ 322 2001 716 720
  14. 14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
  15. 15 S.M. Grundy J.I. Cleeman S.R. Daniels American Heart Association National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2005 2735 2752
  16. 16 International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome . Brussels, Belgium: IDF Communications; 2006. Available here . Accessed September 1, 2008.
  17. 17 A.M. Sharma R. Padwal Obesity is a sign–over-eating is a symptom: an aetiological framework for the assessment and management of obesity Obes Rev 11 2010 362 370
  18. 18 P. Hollander Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes Diabetes Spectrum 20 2007 159 165
  19. 19 A.A. Gorin H.M. Niemeier P. Hogan Binge eating and weight loss outcomes in overweight and obese individuals with type 2 diabetes: results from the Look AHEAD trial Arch Gen Psychiatry 65 2008 1447 1455
  20. 20 P.M. Ribisl W. Lang S.A. Jaramillo Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial Diabetes Care 30 2007 2679 2684
  21. 21 R.R. Grunstein K. Stenlof J.A. Hedner Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity Sleep 30 2007 703 710
  22. 22 R.R. Wing M.D. Marcus L.H. Epstein Type II diabetic subjects lose less weight than their overweight nondiabetic spouses Diabetes Care 10 1987 563 566
  23. 23 A.M. Dattilo P.M. Kris-Etherton Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis Am J Clin Nutr 56 1992 320 328
  24. 24 D.J. Goldstein Beneficial health effects of modest weight loss Int J Obes Relat Metab Disord 16 1992 397 415
  25. 25 P.J. Elmer R. Grimm Jr. B. Laing Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS) Prev Med 24 1995 378 388
  26. 26 J. Tuomilehto J. Lindström J.G. Eriksson Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
  27. 27 W.C. Knowler E. Barrett-Connor S.E. Fowler Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
  28. 28 P. Sumithran L.A. Prendergast E. Delbridge Long-term persistence of hormonal adaptations to weight loss N Engl J Med 365 2011 1597 1604
  29. 29 National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report Obes Res 6 suppl 2 1998 51S 209S
  30. 30 Look AHEAD Research Group R.R. Wing Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial Arch Intern Med 170 2010 1566 1575
  31. 31 T.A. Wadden D.S. West R.H. Neiberg One-year weight losses in the Look AHEAD study: factors associated with success Obesity 17 2009 713 722
  32. 32 The American Diabetes Association's (ADA) evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care. Diabetes Care January 2012 vol. 35 no. Supplement 1.
  33. 33 W.C. Willett W.H. Dietz G.A. Colditz Guidelines for healthy weight N Engl J Med 341 1999 427 434
  34. 34 D.F. Williamson T.J. Thompson M. Thun Intentional weight loss and mortality among overweight individuals with diabetes Diabetes Care 23 2000 1499 1504
  35. 35 K.N. Pavlou S. Krey W.P. Steffee Exercise as an adjunct to weight loss and maintenance in moderately obese subjects Am J Clin Nutr 49 5 suppl 1989 1115 1123
  36. 36 R.R. Wing J.O. Hill Successful weight loss maintenance Annu Rev Nutr 21 2001 323 341
  37. 37 R.R. Wing M.G. Goldstein K.J. Acton Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity Diabetes Care 24 2001 117 123
  38. 38 B.J. Rolls E.L. Morris L.S. Roe Portion size of food affects energy intake in normal-weight and overweight men and women Am J Clin Nutr 76 2002 1207 1213
  39. 39 B.J. Rolls L.S. Roe J.S. Meengs Salad and satiety: energy density and portion size of a first-course salad affect energy intake at lunch J Am Diet Assoc 104 2004 1570 1576
  40. 40 R.R. Wing R.W. Jeffery Outpatient treatments of obesity: a comparison of methodology and clinical results Int J Obes 3 1979 261 279
  41. 41 G.A. Bennett Behaviour therapy for obesity: a quantitative review of the effects of selected treatment characteristics on outcome Behav Ther 17 1986 554 562
  42. 42 B.A. Swinburn L.G. Walter B. Arroll The green prescription study: a randomized controlled trial of written exercise advice provided by general practitioners Am J Public Health 88 1998 288 291
  43. 43 D.N. Logsdon C.M. Lazaro R.V. Meier The feasibility of behavioral risk reduction in primary medical care Am J Prev Med 5 1989 249 256
  44. 44 M.K. Campbell B.M. DeVellis V.J. Strecher Improving dietary behavior: the effectiveness of tailored messages in primary care settings Am J Public Health 84 1994 783 787
  45. 45 B.S. Lewis W.D. Lynch The effect of physician advice on exercise behavior Prev Med 22 1993 110 121
  46. 46 Y. Freedhoff A.M. Sharma Best Weight: A Practical Guide to Office-Based Obesity Management 2010 Canadian Obesity Network, Canada
  47. 47 P.A. Hollander S.C. Elbein I.B. Hirsch Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study Diabetes Care 21 1998 1288 1294
  48. 48 National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity JAMA 276 1996 1907 1915
  49. 49 A.J. Scheen P.J. Lefèbvre Antiobesity pharmacotherapy in the management of type 2 diabetes Diabetes Metab Res Rev 16 2000 114 124
  50. 50 N. Finer S.R. Bloom G.S. Frost Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study Diabetes Obes Metab 2 2000 105 112
  51. 51 S.B. Heymsfield K.R. Segal J. Hauptman Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults Arch Intern Med 160 2000 1321 1326
  52. 52 D.C.W. Lau Surgical options for patients with type 2 diabetes: a review of current and emerging therapies Can Diabetes 23 2010 3 13
  53. 53 F. Abbatini M. Rizzello G. Casella Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes Surg Endosc 24 2010 1005 1010
  54. 54 G. Mingrone S. Panunzi A. De Gaetano Bariatric surgery versus conventional medical therapy for type 2 diabetes N Engl J Med 366 2012 1577 1585
  55. 55 P.R. Schauer S.R. Kashyap K. Wolski Bariatric surgery versus intensive medical therapy in obese patients with diabetes N Engl J Med 366 2012 1567 1576
  56. 56 Diabetes Program Prevention Research Group Reduction in the incidence of Type 2 diabetes with lifestyle or metformin N Engl J Med 346 2002 393 403
  57. 57 S.E. Kahn S.M. Haffner M.A. Heise ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
  58. 58 J. Rosenstock D.R. Hassaman R.D. Madder Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized multicenter study Diabetes Care 27 2004 1265 1270
  59. 59 I. De Leeuw P. Vague J.L. Selam Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin Diabetes Obes Metab 7 2005 73 82
  60. 60 J. Rosenstock S.L. Schwartz C.M. Clark Jr. Basal insulin therapy in patients with type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin Diabetes Care 24 2001 631 636
  61. 61 R.A. DeFronzo A.M. Goodman Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus N Engl J Med 333 1995 541 549
  62. 62 R. Coniff J. Sharpiro D. Robbins Reduction of glycosylated haemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM Diabetes Care 18 1995 831 843
  63. 63 P. Hollander X. Pi Sunyer R. Coniff Acarbose in the treatment of type 1 diabetes Diabetes Care 20 1997 248 254
  64. 64 B. Ahrén M. Landin-Olsson P.A. Jansson Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagons levels in type 2 diabetes J Clin Endocrinol Metab 89 2004 2078 2084
  65. 65 R. Scott M. Wu M. Sanchez P. Stein Efficacy and tolerability of the dipeptidylpeptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int J Clin Pract 61 2007 171 180
  66. 66 R.E. Ratner D. Maggs L.L. Nielsen Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus Diabetes Obes Metab 8 2006 419 428
  67. 67 M. Nauck A. Frid K. Hermansen LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 32 2009 84 90
Reproduced with permission from Canadian Journal of Diabetes © 2013 Canadian Diabetes Association. To cite this article, please refer to For citation.

*The Canadian Diabetes Association is the registered owner of the name Diabetes Canada. All content on guidelines.diabetes.ca, CPG Apps and in our online store remains exactly the same. For questions, contact communication@diabetes.ca.